-
Patients like quality, satisfaction surveys; Cigna stops paying for 'avoidable' conditions; States participating in QI institute; More hospitals offering palliative care; AHRQ resource features 100 innovations and tools; NCQA to expand quality program
-
-
Looking at CAD through the PERISCOPE; Addressing Agitation and Aggression in Persons with Advanced Dementia; It Used To Be Easier To Treat Sinusitis; CAC: A kinder, Gentler Way to Predict Cardiovascular Risk; Was Mae West Right? CV Risk Reduction: Too Much of A Good Thing is Wonderful; Midlife Contraception
-
-
-
CHICAGO Growth in the cardiovascular device market has slowed recently as safety issues with first-generation drug-eluting stents (DES) have combined with controversy re-garding the benefits of interventional therapy, compared to medical treatment, to drive decreased utilization.
-
A combination of disappointing data and urging by a panel of physicians against blockbuster cholesterol drug Vytorin dented two pharma giants, as the annual meeting of the American College of Cardiology (Washington) got under way in Chicago.
-
Clot-busting drug therapy, when administered to patients after a stroke, appears to work more effectively if the patient already has been on an anti-platelet medication. However, this might also increase the risk for bleeding within the brain.
-
One of the ongoing battles pitting "minimally invasive" against open surgical approaches is in clearing the carotid arteries to avoid stroke, or as therapy following stroke.
-
The Centers for Medicare & Medicaid have been especially busy in the cardiovascular sector the past few weeks, resisting coverage, or added coverage, in some areas, approving broader coverage in at least one sector.
